Pyrogennesis and Xebec reached very nearly the same highs.
At $0.75, Xebec trades at .4X book value
Pyrogennesis trades at 7X book.
It's worth a thought
Up to date consensus estimates
With Q2 numbers less than a month away, it's time to visit the latest analyst's estimates.
Of the 8 analysts projecting specific numbers, the low estimate for Q2 revenues is $42.8m, the high estimate is $53m, and the mean is $46.36m.
Last year's Q2 revenues were $32.66m.
The low projection for Q3 revenues ( Sept 2022 ) is $49.59m, the high is $72.5m, and the average is $55.52m.
For fiscal year 2022, the low revenue estimate is $192.79m, the high estimate is $241.8m, and the average estimate is $204.59M.
The estimates for 2023 range from $240m at the low end to $364.58m at the high end, the average being $286.43 million.
As you can see, analyst's estimates are all over the board ( no pun intended )
As you can also see, the mean estimate for 2022 revenues implies yoy revenue growth of 62.5%.
If you're looking to sell your Xebec shares, I would strongly suggest now is not the time to do it.
Xebec isn't getting smaller
The market is, but the company isn't.